Effect of diabetes on islet area and beta-cell function

Area of Science:

• Endocrinology
• Diabetes Research
• Pancreatic Islet Biology

Background:

• Beta-cell dysfunction is central to diabetes pathogenesis.
• Streptozotocin is a commonly used agent to induce experimental diabetes.

Purpose of the Study:

• To investigate the effects of low-dose streptozotocin on beta-cell function and islet mass in mice.
• To establish a model of fasting hyperglycemia associated with beta-cell loss.

Main Methods:

• Isolated perfused mouse pancreas model.
• In situ dithizone staining for morphometrical analysis of islets of Langerhans.
• Streptozotocin (40 mg/kg/day for 5 days) administration.
• Measurement of insulin release and assessment of hyperglycemia.

Main Results:

• Islet area correlated with fasted body weight.
• Fasting hyperglycemia was observed 15 days post-streptozotocin treatment.
• Total islet area decreased to 1% and insulin release to 4% of control values by day 15.

Conclusions:

• Low-dose streptozotocin treatment causes significant beta-cell loss and functional impairment.
• This model demonstrates a strong association between hyperglycemia, reduced beta-cell function, and diminished islet mass.